<DOC>
	<DOCNO>NCT01211275</DOCNO>
	<brief_summary>The purpose study investigate effect axitinib , potent angiogenesis inhibitor , tissue clinical outcome combination chemotherapy give patient mesothelioma</brief_summary>
	<brief_title>Standard Chemotherapy With Without Axitinib Malignant Mesothelioma</brief_title>
	<detailed_description>To determine effect addition axitinib standard chemotherapy tissue sample respect micro-vessel density ( MVD ) : expression VEGF-Receptor ; PDGF receptor expression ; extent necrosis apoptosis . To determine safety addition axitinib ( maximum recommend dose maximally 2 x 10 mg per day ) standard treatment cisplatin pemetrexed . To determine feasibility perform ( second ) thoracoscopy 10 week combination treatment cisplatin , pemetrexed axitinib . Serum sample collect tested inhibiting effect tube formation spheroid sprout assay .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>histologically cytologically diagnose malignant mesothelioma age &gt; 18 year Medically suitable limited surgical intervention ( pleural biopsy limit pleurectomy ) Measurable evaluable disease require Ability understand study give sign informed consent include approval accept second thoracoscopic surgical treatment third course No previous chemotherapy Radiotherapy allow give palliation , interval &gt; 4 week , 1/3 bone marrow capacity tumor within irradiation field . WHO performance status = &lt; 2 Adequate organ function evidence follow peripheral blood count serum chemistry study entry : Hematology : ANC= &gt; 1.5 x 109/L , Platelets= &gt; 150 x 109/L , Hemoglobin = &gt; 6,0 mmol/l Chemistry : total serum bilirubin &lt; UNL ; AST ALT= &lt; 2.5xUNL , AP &lt; 5xUNL ( unless bone metastasis present absence liver disease ) Serum creatinine = &lt; 2xUNL Active uncontrolled infection , severe cardiac dysfunction uncorrectable bleeding tendency Previous successful pleurodesis Uncontrolled hypertension Symptomatic peripheral neuropathy = &gt; grade 2 accord NCIC CTC , version 3.0 Presence symptomatic CNS metastasis Unstable peptic ulcer , unstable diabetes mellitus serious disable condition Concomitant administration experimental drug investigation Impaired renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>mesothelioma</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>translational research</keyword>
	<keyword>axitinib</keyword>
</DOC>